Citi analyst David Lebowitz upgraded Intellia Therapeutics to Neutral from Sell with a price target of $39, down from $48. The analyst cites the recent share price decline and the overall potential of the company’s platform for the upgrade. At the current valuation, Intellia’s risk/reward profile is more balanced, the analyst tells investors in a research note. Citi continues to view Intellia’s CRISPR/Cas9 gene-editing platform as a "potentially transformational modality."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NTLA:
- JMP downgrades Intellia on lack of 2023 clinical updates
- Intellia Therapeutics downgraded to Market Perform from Outperform at JMP Securities
- Intellia awarded innovation passport in UK for NTLA-2002
- Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
- ZM, NTLA, or SQ: Which Cathie Wood ARKK Stock Is Most Appealing in 2023?
